Intersect ENT Inc (XENT) Given Average Recommendation of “Hold” by Brokerages

Shares of Intersect ENT Inc (NASDAQ:XENT) have earned an average recommendation of “Hold” from the ten brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $39.00.

Several brokerages have recently commented on XENT. Zacks Investment Research downgraded Intersect ENT from a “buy” rating to a “hold” rating in a research note on Tuesday, January 22nd. BidaskClub downgraded Intersect ENT from a “hold” rating to a “sell” rating in a research note on Thursday. BTIG Research reissued a “hold” rating on shares of Intersect ENT in a research note on Tuesday, February 26th. ValuEngine raised Intersect ENT from a “hold” rating to a “buy” rating in a research note on Saturday, February 23rd. Finally, TheStreet downgraded Intersect ENT from a “c-” rating to a “d+” rating in a research note on Thursday, January 3rd.

XENT stock traded down $0.37 during trading on Wednesday, reaching $28.59. 350,656 shares of the stock were exchanged, compared to its average volume of 261,230. Intersect ENT has a twelve month low of $25.09 and a twelve month high of $42.95. The company has a market cap of $867.09 million, a P/E ratio of -37.62 and a beta of 0.64.

Intersect ENT (NASDAQ:XENT) last posted its quarterly earnings results on Monday, February 25th. The medical equipment provider reported ($0.16) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.16). Intersect ENT had a negative return on equity of 19.04% and a negative net margin of 21.13%. The business had revenue of $32.80 million for the quarter, compared to the consensus estimate of $32.68 million. During the same period in the prior year, the business earned ($0.11) EPS. The firm’s revenue for the quarter was up 11.2% on a year-over-year basis. Equities analysts predict that Intersect ENT will post -1.07 EPS for the current year.

In other news, CFO Jeryl L. Hilleman sold 30,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $32.07, for a total value of $962,100.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Robert H. Binney, Jr. sold 3,495 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $31.98, for a total value of $111,770.10. The disclosure for this sale can be found here. Over the last three months, insiders sold 43,495 shares of company stock valued at $1,365,170. Company insiders own 5.90% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in XENT. NumerixS Investment Technologies Inc grew its holdings in shares of Intersect ENT by 43.0% in the fourth quarter. NumerixS Investment Technologies Inc now owns 2,200 shares of the medical equipment provider’s stock valued at $60,000 after acquiring an additional 662 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Intersect ENT by 183.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,617 shares of the medical equipment provider’s stock valued at $74,000 after acquiring an additional 1,694 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of Intersect ENT by 14.8% in the fourth quarter. Legal & General Group Plc now owns 5,353 shares of the medical equipment provider’s stock valued at $151,000 after acquiring an additional 690 shares in the last quarter. Meeder Asset Management Inc. grew its holdings in shares of Intersect ENT by 215.0% in the fourth quarter. Meeder Asset Management Inc. now owns 5,604 shares of the medical equipment provider’s stock valued at $159,000 after acquiring an additional 3,825 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in shares of Intersect ENT by 15.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 8,194 shares of the medical equipment provider’s stock valued at $230,000 after acquiring an additional 1,114 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Intersect ENT Company Profile

Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.

Further Reading: The Role of a Fiduciary and Individual Investors

Analyst Recommendations for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.